Skip to main content
. 2020 Oct 23;22(12):669–700. doi: 10.1021/acscombsci.0c00099

Figure 7.

Figure 7

Targeting molecular pathways in anticancer therapy using paclitaxel–siRNA-loaded nanoparticles. SiRNA–Beclin inhibits autophagy and enhances the antitumor activity of paclitaxel. SiRNA–STMN1, VEGF, Bcl-2, FAK, survivin, and NF-κB sensitize cancer cells to paclitaxel chemotherapy. The potential of siRNA and paclitaxel in anticancer therapy is boosted when they are loaded into nanoparticles.